MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding MAIA Biotechnology, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 20 | 20 | 0 |
| Shares | 1.39M | 1.48M | +86.3K (+6.2%) |
| Value | $2.75M | $2.26M | −$493.0K (−17.9%) |
New holders (3)
Institutions that held MAIA Biotechnology, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Naviter Wealth, LLC | 10,000 | $16.2K | 0.00% |
| UBS Group AG | 300 | $459 | 0.00% |
| Jones Financial Companies LLLP | 228 | $369 | 0.00% |
Sold out (3)
Institutions that held MAIA Biotechnology, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Jane Street Group, LLC | 39,057 | $77.3K |
| Royal Bank of Canada | 3,000 | $6.00K |
| Tucker Asset Management LLC | 341 | $675 |